The favourable prognostic value of oestrogen receptor β immunohistochemical expression in breast cancer

Journal of Clinical Pathology

Volumn 57, Issue 5, 2004, Pages 523-528

  Nakopoulou, L ^a   Lazaris, A C ^a   Panayotopoulou, E G ^a   Giannopoulou, I ^a   Givalos, N ^a   Markaki, S ^b   Keramopoulos, A ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR BETA; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN P53; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TISSUE SECTION; AGED; BREAST TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 2442553813     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.008599     Document Type: Article

References (29)

1. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists' Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
2. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
3. Jensen EV, Chen G, Palmieri C, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 2001;98:15197-202.
4. Saji S, Jensen EV, Nilsson S, et al. Estrogen receptors α and β in the rodent mammary gland. Proc Natl Acad Sci U S A 2000;97:337-42.
5. Speirs V, Skliris GP, Burdall SE, et al. Distinct expression patterns of ERα and ERβ in normal human mammary gland. J Clin Pathol 2002;55:371-4.
6. Saunders PTK, Millor MR, Williams K, et al. Expression of oestrogen receptor beta (ERβ) protein in human breast cancer biopsies. Br J Cancer 2002;86:250-6.
7. Järvinen TAH, Pelto-Huikko M, Holli K, et al. Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade and proliferation rate in breast cancer. Am J Pathol 2000;156:29-35.
8. Palmieri C, Cheng GJ, Saji S, et al. Estrogen receptor beta in breast cancer. Endocr Relat Cancer 2002;9:1-13.
9. Bièche I, Parfait B, Laurendeau I, et al. Quantification of estrogen receptor α and β expression in sporadic breast cancer. Oncogene 2001;20:8109-115.
10. Lazennec G, Bresson D, Lucas A, et al. ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001;142:4120-30.
11. Mann S, Laucirica R, Carlson N, et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 2001;32:113-18.
12. Speirs V. Oestrogen receptor beta in breast cancer: good, bad or still too early to tell? J Pathol 2002;197:143-7.
13. WHO. Histological typing of breast tumours. In: Hartman WH, Uzello L, Sobin LH, et al. International histological classification of tumours. Geneva: World Health Organisation, 1981:15-25.
14. Rosen PP, Oberman HA. Tumors of the mammary gland. In: Rosai J, ed. Atlas of tumor pathology. Washington: Armed Forces Institute of Pathology, 1992:3-7.
15. Rabbins P, Pinder S, De Klerk N. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995;28:873-9.
16. Nakopoulou L, Michalopoulou A, Giannopoulou I, et al. Bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining. Histopathology 1999;34:310-19.
17. Nakapoulou L, Lazaris AC, Kavantzas N, et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000;68:137-43.
18. Nakopoulou L, Zervas A, Lazaris ACh, et al. Predictive value of topaisomerase IIa immunostaining in urothelial bladder carcinoma. J Clin Pathol 2001;54:309-13.
19. Girdler F, Browell DA, Cunliffe WJ, et al. Use of the monoclonal antibody DAKO-ERbeta (8D5-1) to measure oestrogen receptor beta in breast cancer cells. Cytometry 2001;45:65-72.
20. Omoto Y, Inoue S, Ogawa S, et al. Clinical value of the wild-type estrogen receptor β expression in breast cancer. Cancer Lett 2001;163:207-12.
21. Skliris GP, Carder PJ, Lansdown MRJ, et al. Immunohistochemical detection of ERβ in breast cancer: towards more detailed receptor profiling? Br J Cancer 2001;84:1095-8.
22. Kurebayashi J, Otsuki T, Kunisue H, et al. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000;6:512-18.
23. Miyoshi Y, Taguchi T, Gustafsson J-Å, et al. Clinicopathological characteristics of estrogen receptor-β-positive human breast cancers. Jpn J Cancer Res 2001;92:1057-61.
24. Speirs V, Parkes AT, Kerin MJ, et al. Coexpression of estrogen receptor α and β: poor prognostic factors in human breast cancer? Cancer Res 1999;59:525-8.
25. Rudolph P, Olsson H, Bonatz G, et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999;187:207-16.
26. Lynch BJ, Guinee DG Jr, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997;28:1180-8.
27. Knowlden JM, Gee JM, Robertson JF, et al. A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. Int J Cancer 2000;89:209-12.
28. Nakopoulou L, Giannopoulou I, Lazaris AC, et al. The favorable prognostic impact of tissue inhibitor of matrix metalloprotoinases-1 protein expression in breast cancer cells. APMIS 2003;111:1027-36.
29. Kent Osborne C. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227-38.